医学
血栓形成
支架
急性冠脉综合征
心脏病学
内科学
重症监护医学
心肌梗塞
作者
Ahmed El‐Medany,Vanessa Kandoole,Nicholas Lonsdale,Gemina Doolub,Ioannis Felekos
出处
期刊:Current Cardiology Reviews
[Bentham Science]
日期:2023-01-01
卷期号:19 (1)
被引量:1
标识
DOI:10.2174/1573403x18666220512142019
摘要
: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been demonstrated as a major risk factor in inducing coronary stent thrombosis due to its propensity to create a pro-thrombotic state. This review explores the mechanisms that may contribute to the increased thrombosis risk seen in COVID-19. Furthermore, we discuss the patient and haematological factors that predispose to an increased risk of stent thrombosis, as well as the role of certain antiplatelet and anticoagulation therapies, including ticagrelor and enoxaparin, that may reduce the likelihood and severity of in-stent thrombosis, in SARS-CoV-2 infection. To counter the proinflammatory and pro-thrombotic state shown in COVID-19, anti-thrombotic therapy in the future may be optimised using point-of-care platelet inhibition testing and inflammation-modifying therapies. Large-scale randomised trials with long-term follow-up are increasingly necessary to assess the intersection of COVID-19 and stent optimisation as well as the reduction of stent thrombosis after drug-eluting stent (DES) implantation.
科研通智能强力驱动
Strongly Powered by AbleSci AI